Scroll Top
2bg-image
3bg-image

Targeting glucocerebrosidase with structurally targeted allosteric regulators corrects abnormal phenotypes in models of Parkinson’s disease

April 12th- 15th 2022 11:20 – 11:50 a.m. ET

Learn More

Bottom-Back

Latest Articles

Clear Filters
April 12, 2022
Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting
Read More
September 9, 2020
Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program
Read More
August 30, 2024
Gain Therapeutics reports positive data from Phase I Parkinson’s treatment trial
Read More